Download integrale PDF - Progetto Mondiale Asma - Ginasma

190. Kips JC, O’Connor BJ, Inman MD, Svensson K, Pauwels
RA, O’Byrne PM. A long-term study of the
antiinflammatory effect of low-dose budesonide plus
formoterol versus high-dose budesonide in asthma.
Am J Respir Crit Care Med 2000; 161: 996-1001.
191. Wallaert B, Brun P, Ostinelli J, Murciano D, Champel F,
Blaive B, et al. A comparison of two long-acting
beta-agonists, oral bambuterol and inhaled salmeterol,
in the treatment of moderate to severe asthmatic
patients with nocturnal symptoms.
The French Bambuterol Study Group.
Respir Med 1999; 93: 33-8.
192. Crompton GK, Ayres JG, Basran G, Schiraldi G,
Brusasco V, Eivindson A, et al. Comparison of oral
bambuterol and inhaled salmeterol in patients with
symptomatic asthma and using inhaled corticosteroids.
Am J Respir Crit Care Med 1999; 159: 824-8.
193. Lipworth BJ. Leukotriene-receptor antagonists.
Lancet 1999; 353: 57-62.
194. Drazen JM, Israel E, O’Byrne PM. Treatment of asthma
with drugs modifying the leukotriene pathway.
N Engl J Med 1999; 340: 197-206.
195. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R,
Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on
cellular mediators of inflammation: bronchoalveolar
lavage fluid findings after segmental antigen challenge.
Am J Respir Crit Care Med 1998; 157: 1381-9.
196. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP,
Wei LX, et al. Montelukast reduces airway eosinophilic
inflammation in asthma: a randomized, controlled trial.
Eur Respir J 1999; 14: 12-8.
197. Barnes NC, Miller CJ. Effect of leukotriene receptor
antagonist therapy on the risk of asthma exacerbations
in patients with mild to moderate asthma: an integrated
analysis of zafirlukast trials.
Thorax 2000; 55: 478-83.
198. Bleecker ER, Welch MJ, Weinstein SF, Kalberg C,
Johnson M, Edwards L, et al. Low-dose inhaled
fluticasone propionate versus oral zafirlukast in the
treatment of persistent asthma.
J Allergy Clin Immunol 2000; 105: 1123-9.
199. Laviolette M, Malmstrom K, Lu S, Chervinsky P,
Pujet JC, Peszek I, et al. Montelukast added to inhaled
beclomethasone in treatment of asthma.
Montelukast/Beclomethasone Additivity Group.
Am J Respir Crit Care Med 1999; 160: 1862-8.
200. Barnes N, Wei LX, Reiss TF, Leff JA, Shingo S, Yu C,
Edelman JM. Analysis of montelukast in mild persistent
asthmatic patients with near-normal lung function.
Respir Med. 2001; 95: 379-86
162 PROGRAMMA DI TRATTAMENTO DELL’ASMA IN SEI PARTI
201. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ,
Finn AF, et al. Randomised, placebo controlled trial of
effect of a leukotriene receptor antagonist, montelukast,
on tapering inhaled corticosteroids in asthmatic patients.
BMJ 1999; 319: 87-90.
202. Virchow JC, Prasse A, Naya I, Summerton L, Harris A.
Zafirlukast improves asthma control in patients receiving
high-dose inhaled corticosteroids.
Am J Respir Crit Care Med 2000; 162: 578-85.
203. Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J,
Sobradillo V, Valencia A, Verea H, Viejo JL, Villasante C,
Gonzalez-Esteban J, Picado C; CASIOPEA (Capacidad
de Singulair Oral en la Prevencion de Exacerbaciones
Asmaticas) Study Group. Effect of montelukast added to
inhaled budesonide on control of mild to moderate
asthma.
Thorax. 2003; 58: 204-10.
204. Price DB, Hernandez D, Magyar P, Fiterman J,
Beeh KM, James IG, Konstantopoulos S, Rojas R, van
Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes
with Montelukast as a Partner Agent to Corticosteroid
Therapy (COMPACT) International Study Group.
Randomised controlled trial of montelukast plus inhaled
budesonide versus double dose inhaled budesonide in
adult patients with asthma.
Thorax. 2003 ; 58: 211-6.
205. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW,
Rickard KA. Comparison of inhaled salmeterol and oral
zafirlukast in patients with asthma.
J Allergy Clin Immunol 1999; 103: 1075-80.
206. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM,
Greening A, Haahtela T, Holgate ST, Picado C, Leff JA.
Montelukast or salmeterol combined with an inhaled
steroid in adult asthma: design and rationale of a
randomized, double-blind comparative study (the
IMPACT Investigation of Montelukast as a Partner Agent
for Complementary Therapy-trial).
Respir Med. 2000 ; 94: 612-21
207. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ.
Effects of montelukast on surrogate inflammatory
markers in corticosteroid-treated patients with asthma.
Am J Respir Crit Care Med. 2003; 167: 1232-8.
208. Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O,
Bochenek G, Kumlin M, et al. Benefits from adding the
5-lipoxygenase inhibitor zileuton to conventional therapy
in aspirin-intolerant asthmatics.
Am J Respir Crit Care Med 1998; 157: 1187-94.
209. Tonelli M, Zingoni M, Bacci E, Dente FL, Di Franco A,
Giannini D, Taccola M, Vagaggini B, Paggiaro PL. Shortterm
effect of the addition of leukotriene receptor
antagonists to the current therapy in severe asthmatics.
Pulm Pharmacol Ther 2003; 16: 237-240.